A Prospective Multicenter Randomized Controlled Study of Nicorandil on Chronic Heart Failure

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002250

Enrollment

Unknown

Registered

2012-06-07

Start date

2012-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure

Interventions

1:Nicorandil 5mg tid

2:standard therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: age>=18; symptoms,signs and examine of CHF; patients with informed Consent

Exclusion criteria

Exclusion criteria: patients with therapy of no-medicine;Chronic Heart Failure induced in Dongenital Heart Disease, Valvular Heart Disease, Thyrotoxicosis, Pulmonary Hypertension; Orthostatic hypotension; Liver and renal insufficiency; Glaucoma; Active peptic ulcer.

Design outcomes

Primary

Measure	Time frame
six minute walk test;	—

Countries

China

Contacts

Public ContactMA Yi-tong

myt-xj@163.com+86 0991 4366169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026